COPD is the second highest cause of death in India

18th June 2019

COPD in India: Chronic Obstructive Pulmonary Disease (COPD) was the second highest cause of death in India after heart disease in 2017, killing 1 million (958,000) Indians that year, according to University of Washington’s Global Burden of Disease study, 2018.

From moderate chronic bronchitis to severe emphysema, COPD covers a range of debilitating lung conditions that limit airflow to the lungs.

The most common symptoms of COPD are breathlessness, or a ‘need for air’, excessive sputum production, and a chronic cough. However, COPD is not just simply a “smoker’s cough”, but a under-diagnosed, life threatening lung disease that may progressively lead to death.

The World Health Organisation (WHO) recognises that bronchodilator medications are crucial for symptomatic management of COPD and to effectively treat severe exacerbations of the disease.

How can Aerogen Help? 

Aerogen Ultra improves lung volumes in COPD patients

Study reveals that bronchodilator delivery using Aerogen Ultra resulted in a significant improvement in FVC in COPD patients experiencing acute exacerbation along with a significant improvement in symptom scores.[1]

Data released at Irish Thoracic Society, Dublin assessed bronchodilator response during acute exacerbation of COPD using a vibrating mesh nebuliser versus jet nebuliser for bronchodilator delivery. The study randomised 32 patients to a standard jet nebuliser treatment or the Aerogen Ultra. The Aerogen Ultra group achieved a significantly greater improvement in post-bronchodilator FVC compared to the Jet neb group and only the Aerogen Ultra group demonstrated a significant improvement in post-bronchodilator BORG breathlessness score.

Commenting on the results, Prof Richard Costello, Chairman of the Asthma Society of Ireland Medical Advisory Committee and consultant chest physician at Beaumont Hospital, said “Recovery from COPD exacerbation is associated with increases in respirable lung volume. Accelerating these changes through improved bronchodilator delivery could hasten recovery. We have demonstrated a significant improvement in lung volume with an accompanied decrease in patient’s breathlessness score during COPD exacerbation with just a single 2.5mg salbutamol dose delivered with the Aerogen Ultra nebuliser. [2]”.

Download the full study poster here.

Aerogen in India

Aerogen, the world leader in aerosol drug delivery, continues to expand its international activities with the opening of its Indian headquarters in Delhi in April 2019. The office is located in the ABW Rectangle One Building (131) in New Delhi.

Managed by Aerogen Sales Director Asia Pacific, Richard Featherstone, and supported by Country Manager India & Subcontinent, Rajiv Julka, the team will be made up to include five Clinical Specialists that will be located across India. Read more here.

For further information please contact or

Aerogen India Ltd.131, ABW Rectangle One Building, D-4, Saket District Centre, Saket, New Delhi 110017.

Phone +91 11 41422577

More News & Events